Funding for this research was provided by:
National Cancer Institute (P30CA016520)
University of Pennsylvania Bladder Cancer Biomarker Discovery Fund (Not applicable)
Article History
Received: 26 October 2018
Accepted: 27 March 2019
First Online: 22 May 2019
Ethics approval and consent to participate
: We conducted the present analysis under a data use agreement with SWOG and with approval of the University of Pennsylvania Institutional Review Board. The study is registered under “Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710” in ClinicalTrials.gov (NCT02756637).
: Not applicable.
: JC reports employee status at Elekta Inc, an oncology medical device company. AS and W-TH declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.